Methotrexate to treat hand osteoarthritis with synovitis (METHODS): an Australian, multisite, parallel-group, double-blind, randomised, placebo-controlled trial
- PMID: 37839420
- DOI: 10.1016/S0140-6736(23)01572-6
Methotrexate to treat hand osteoarthritis with synovitis (METHODS): an Australian, multisite, parallel-group, double-blind, randomised, placebo-controlled trial
Abstract
Background: Hand osteoarthritis is a disabling condition with few effective therapies. Hand osteoarthritis with synovitis is a common inflammatory phenotype associated with pain. We aimed to examine the efficacy and safety of methotrexate at 6 months in participants with hand osteoarthritis and synovitis.
Methods: In this multisite, parallel-group, double-blind, randomised, placebo-controlled trial, participants (aged 40-75 years) with hand osteoarthritis (Kellgren and Lawrence grade ≥2 in at least one joint) and MRI-detected synovitis of grade 1 or more were recruited from the community in Melbourne, Hobart, Adelaide, and Perth, Australia. Participants were randomly assigned (1:1) using block randomisation, stratified by study site and self-reported sex, to receive methotrexate 20 mg or identical placebo orally once weekly for 6 months. The primary outcome was pain reduction (measured with a 100 mm visual analogue scale; VAS) in the study hand at 6 months assessed in the intention-to-treat population. Safety outcomes were assessed in all randomly assigned participants. This trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12617000877381).
Findings: Between Nov 22, 2017, and Nov 8, 2021, of 202 participants who were assessed for eligibility, 97 (48%) were randomly assigned to receive methotrexate (n=50) or placebo (n=47). 68 (70%) of 97 participants were female and 29 (30%) were male. 42 (84%) of 50 participants in the methotrexate group and 40 (85%) of 47 in the placebo group provided primary outcome data. The mean change in VAS pain at 6 months was -15·2 mm (SD 24·0) in the methotrexate group and -7·7 mm (25·3) in the placebo group, with a mean between-group difference of -9·9 (95% CI -19·3 to -0·6; p=0·037) and an effect size (standardised mean difference) of 0·45 (0·03 to 0·87). Adverse events occurred in 31 (62%) of 50 participants in the methotrexate group and 28 (60%) of 47 participants in the placebo group.
Interpretation: Treatment of hand osteoarthritis and synovitis with 20 mg methotrexate for 6 months had a moderate but potentially clinically meaningful effect on reducing pain, providing proof of concept that methotrexate might have a role in the management of hand osteoarthritis with an inflammatory phenotype.
Funding: National Health and Medical Research Council of Australia.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests We declare no competing interests.
Comment in
-
Inflammation is a relevant treatment target in osteoarthritis.Lancet. 2023 Nov 11;402(10414):1725-1726. doi: 10.1016/S0140-6736(23)01726-9. Epub 2023 Oct 12. Lancet. 2023. PMID: 37839421 No abstract available.
Similar articles
-
Study protocol for a randomised controlled trial of diacerein versus placebo to treat knee osteoarthritis with effusion-synovitis (DICKENS).Trials. 2022 Sep 11;23(1):768. doi: 10.1186/s13063-022-06715-w. Trials. 2022. PMID: 36089595 Free PMC article.
-
METHODS - A randomised controlled trial of METhotrexate to treat Hand Osteoarthritis with Synovitis: study protocol for a randomised controlled trial.BMC Musculoskelet Disord. 2021 Nov 15;22(1):953. doi: 10.1186/s12891-021-04842-0. BMC Musculoskelet Disord. 2021. PMID: 34781952 Free PMC article.
-
Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial.Lancet. 2019 Nov 30;394(10213):1993-2001. doi: 10.1016/S0140-6736(19)32489-4. Epub 2019 Nov 11. Lancet. 2019. PMID: 31727410 Clinical Trial.
-
Chondroitin for osteoarthritis.Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD005614. doi: 10.1002/14651858.CD005614.pub2. Cochrane Database Syst Rev. 2015. PMID: 25629804 Free PMC article. Review.
-
Oral herbal therapies for treating osteoarthritis.Cochrane Database Syst Rev. 2014 May 22;2014(5):CD002947. doi: 10.1002/14651858.CD002947.pub2. Cochrane Database Syst Rev. 2014. PMID: 24848732 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical